Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

International Journal of Neuropsychopharmacology

Volumn 13, Issue 7, 2010, Pages 951-960

  Vernaleken, Ingo ^a,b   Janouschek, Hildegard ^a,b   Raptis, Mardjan ^a   Hellmann, Sandra ^a,b   Veselinovic, Tanja ^a,b   Bröcheler, Anno ^a,b   Boy, Christian ^c   Cumming, Paul ^d   Hiemke, Christoph ^e   Rsch, Frank ^e   Schäfer, Wolfgang M ^a   Gründer, Gerhard ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JARA TRANSLATIONAL BRAIN MEDICINE   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antipsychotics; D2 3 receptor occupancy; positron emission tomography; preferential extrastriatal binding; quetiapine; schizophrenia

Indexed keywords

DESMETHOXYFALLYPRIDE F 18; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; QUETIAPINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DIBENZOTHIAZEPINE DERIVATIVE; N ((1 ALLYL 2 PYRROLIDINYL)METHYL) 5 (3 FLUOROPROPYL) 2,3 DIMETHOXYBENZAMIDE; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; NEUROLEPTIC AGENT; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CYCLOTHYMIA; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PERSONALITY DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; PUTAMEN; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS; BINDING COMPETITION; DRUG EFFECT; METABOLISM; MIDDLE AGED; SCINTISCANNING; TEMPORAL LOBE; VISUAL CORTEX;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BINDING, COMPETITIVE; CORPUS STRIATUM; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TEMPORAL LOBE; VISUAL CORTEX; YOUNG ADULT;

EID: 77957234962     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000374     Document Type: Article

References (41)

1. Agid O, Mamo D, Ginovart N, Vitcu I, et al. (2007). Striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 32, 1209-1215. (Pubitemid 46788848)
2. Brown RM, Crane AM, Goldman PS (1979). Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Research 168, 133-150.
3. Burris KD, Molski TF, Xu C, Ryan E, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 302, 381-389. (Pubitemid 34680462)
4. Castelli MP,Mocci I, Sanna AM, Gessa GL, et al. (2001). (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2). receptors. European Journal of Pharmacology 432, 143-147.
5. Catafau AM, Penengo MM, Nucci G, Bullich S, et al. (2008). Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. Journal of Psychopharmacology 22, 882-894.
6. Devoto P, Flore G (2006). On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Current Neuropharmacology 4, 115-125. (Pubitemid 44027872)
7. Farde L, Eriksson L, Blomquist G, Halldin C (1989). Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. Journal of Cerebral Blood Flow and Metabolism 9, 696-708. (Pubitemid 19239491)
8. Farde L, Nordström AL, Wiesel FA, Pauli S, et al. (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
9. Farde L, Suhara T, Nyberg S, Karlsson P, et al. (1997). A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berlin) 133, 396-404. (Pubitemid 27462815)
10. Frankle WG (2007). Neuroreceptor imaging studies in schizophrenia. Harvard Review of Psychiatry 15, 212-232.
11. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, et al. (1998). Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berlin) 135, 119-126. (Pubitemid 28055494)
12. Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, et al. (2001). D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. European Neuropsychopharmacology 11, 105-110. (Pubitemid 32335553)
13. Grü nder G, Fellows C, Janouschek H, Veselinovic T, et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. American Journal of Psychiatry 165, 988-995.
14. Grü nder G, Landvogt C, Vernaleken I, Buchholz HG, et al. (2006). The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31, 1027-1035.
15. Grü nder G, Siessmeier T, Piel M, Vernaleken I, et al. (2003). Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. Journal of Nuclear Medicine 44, 109-116. (Pubitemid 36077721)
16. Hagberg G, Gefvert O, Bergstrom M, Wieselgren IM, et al. (1998). N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Research 82, 147-160.
17. Ito H, Arakawa R, Takahashi H, Takano H, et al. (2009). No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. International Journal of Neuropsychopharmacology 12, 667-675.
18. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, et al. (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapines antidepressant activity. Neuropsychopharmacology 33, 2303-2312.
19. Kapur S, Seeman P (2000). Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. Journal of Psychiatry and Neuroscience 25, 161-166. (Pubitemid 30233553)
20. Kapur S, Zipursky R, Jones C, Shammi CS, et al. (2000). A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of General Psychiatry 57, 553-559. (Pubitemid 30349435)
21. Kegeles LS, Slifstein M, Frankle WG, Xu X, et al. (2008). Dose-occupancy study of striatal and extrastriatal dopamine D(2) receptors by aripiprazole in schizophrenia with PET and [(18)F]fallypride. Neuropsychopharmacology 33, 3111-3125.
22. Kessler RM, Ansari MS, Riccardi P, Li R, et al. (2006). Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31, 1991-2001. (Pubitemid 44246345)
23. Kü fferle B, Tauscher J, Asenbaum S, Vesely C, et al. (1997). IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berlin) 133, 323-328.
24. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158. (Pubitemid 27024284)
25. Mamo DC, Uchida H, Vitcu I, Barsoum P, et al. (2008). Quetiapine extended-release vs. immediate-release formulation: a positron emission tomography study. Journal of Clinical Psychiatry 69, 81-86. (Pubitemid 351282000)
26. Nordström AL, Farde L, Wiesel FA, Forslund K, et al. (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry 33, 227-235. (Pubitemid 23091497)
27. Olsson H, Farde L (2001). Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. Neuroimage 14, 936-945. (Pubitemid 32929894)
28. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, et al. (1997). Limbic selectivity of clozapine. Lancet 350, 490-491.
29. Sachse J, Koller J, Härtter S, Hiemke C (2006). Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 830, 342-348. (Pubitemid 43075471)
30. Schotte A, Janssen PF, Bonaventure P, Leysen JE (1996a). Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochemical Journal 28, 791-799. (Pubitemid 26414169)
31. Schotte A, Janssen PF, Gommeren W, Luyten WH, et al. (1996b). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin) 124, 57-73. (Pubitemid 26112775)
32. Schotte A, Janssen PF, Gommeren W, Luyten WH, et al. (1996c). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin) 124, 57-73. (Pubitemid 26112775)
33. Stephenson CM, Bigliani V, Jones HM, Mulligan RS, et al. (2000). Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [123I]-epidepride single photon emission tomography(SPET) study. British Journal of Psychiatry 177, 408-415. (Pubitemid 30429293)
34. Talvik M, Nordström AL, Nyberg S, Olsson H, et al. (2001). No support for regional selectivity in clozapine-treated patients: a PET study with [11C]raclopride and [11C]FLB 457. American Journal of Psychiatry 158, 926-930. (Pubitemid 32547623)
35. Tauscher J, Hussain T, Agid O, Verhoeff NP, et al. (2004). Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. American Journal of Psychiatry 161, 1620-1625. (Pubitemid 39201459)
36. Tauscher J, Jones C, Remington G, Zipursky RB, et al. (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Molecular Psychiatry 7, 317-321. (Pubitemid 34280640)
37. Vernaleken I, Cumming P, Gründer G (2008a). Imaging studies - differential action of typical and atypical antipsychotics in a network perspective. Pharmacopsychiatry 41 (Suppl. 1), S60-69.
38. Vernaleken I, Fellows C, Janouschek H, Bröcheler A, et al. (2008b). Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). Journal of Clinical Psychopharmacology 28, 608-617.
39. Vernaleken I, Siessmeier T, Buchholz HG, Hartter S, et al. (2004). High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology 7, 421-430. (Pubitemid 39648072)
40. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, et al. (2008). Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Journal of Child and Adolescent Psychopharmacology 18, 81-98.
41. Xiberas X, Martinot JL, Mallet L, Artiges E, et al. (2001). Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 179, 503-508. (Pubitemid 34031674)